Home Newsletters Immune Regulation News MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia...

MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase Ib/IIa Study in Patients with Ulcerative Colitis

By
Justin.choi
-
0
MRM Health announced that the first patient received MH002 in a Phase Ib/IIa multi-center clinical trial in mild-to-moderate ulcerative colitis.
[MRM Health]

Sorry, but the selected Zotpress account can't be found.

Press Release

RELATED ARTICLES

Exit mobile version